Prevalence and determinants of sarcopenia in community-dwelling older adults in Ireland
- PMID: 37326940
- DOI: 10.1007/s40520-023-02453-4
Prevalence and determinants of sarcopenia in community-dwelling older adults in Ireland
Abstract
Background: Data on the prevalence of sarcopenia among older adults in Ireland are lacking.
Aims: To assess the prevalence and determinants of sarcopenia among community-dwelling older adults in Ireland.
Methods: This cross-sectional analysis involved n = 308 community-dwelling adults aged ≥ 65 y living in Ireland. Participants were recruited via recreational clubs and primary healthcare services. Sarcopenia was defined according to the 2019 European Working Group on Sarcopenia in Older People (EWGSOP2) criteria. Skeletal muscle mass was estimated using bioelectrical impedance analysis, strength was measured via handgrip dynamometry, and physical performance was assessed using the Short Physical Performance Battery. Detailed information was collected on demographics, health, and lifestyle. Dietary macronutrient intake was measured via a single 24 h recall. Binary logistic regression was used to examine potential demographic, health, lifestyle, and dietary determinants of sarcopenia (where both probable and confirmed sarcopenia were combined).
Results: The prevalence of EWGSOP2-defined probable sarcopenia was 20.8% and confirmed sarcopenia was 8.1% (5.8% had severe sarcopenia). Polypharmacy (OR 2.60, 95% confidence interval [CI] 1.3, 5.23), height (OR 0.95, 95% CI 0.91, 0.98), and Instrumental Activities Of Daily Living (IADL) score (OR 0.71, 95% CI 0.59, 0.86) were independently associated with sarcopenia (probable and confirmed combined). There were no independent associations between energy-adjusted macronutrient intakes, as determined by 24 h recall, and sarcopenia.
Conclusion: Sarcopenia prevalence within this sample of community-dwelling older adults in Ireland is broadly similar to other European cohorts. Polypharmacy, lower height, and lower IADL score were independently associated with EWGSOP2-defined sarcopenia.
Keywords: Muscle strength; Older adults; Polypharmacy; Sarcopenia.
© 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
References
-
- Cruz-Jentoft AJ, Bahat G, Bauer J et al (2019) Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 48:16–31. https://doi.org/10.1093/ageing/afy169 - DOI - PubMed
-
- Bischoff-Ferrari HA, Orav JE, Kanis JA et al (2015) Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporos Int 26:2793–2802. https://doi.org/10.1007/s00198-015-3194-y - DOI - PubMed
-
- Schaap LA, van Schoor NM, Lips P et al (2018) Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. J Gerontol A Biol Sci Med Sci 73:1199–1204. https://doi.org/10.1093/gerona/glx245 - DOI - PubMed
-
- Kitamura A, Seino S, Abe T et al (2021) Sarcopenia: prevalence, associated factors, and the risk of mortality and disability in Japanese older adults. J Cachexia Sarcopenia Muscle 12:30–38. https://doi.org/10.1002/jcsm.12651 - DOI - PubMed
-
- Beaudart C, Biver E, Reginster JY et al (2017) Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle 8:238–244. https://doi.org/10.1002/jcsm.12149 - DOI - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources